Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
58.54
-4.95 (-7.80%)
At close: Apr 1, 2025, 4:00 PM
59.65
+1.11 (1.90%)
After-hours: Apr 1, 2025, 5:48 PM EDT
Company Description
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma.
Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Verona Pharma plc
| Country | United Kingdom |
| Founded | 2005 |
| IPO Date | Apr 27, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 209 |
| CEO | David Zaccardelli |
Contact Details
Address: 3 More London Riverside London, SE1 2RE United Kingdom | |
| Phone | 44 20 3283 4200 |
| Website | veronapharma.com |
Stock Details
| Ticker Symbol | VRNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001657312 |
| CUSIP Number | 925050106 |
| ISIN Number | US9250501064 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David S. Zaccardelli Pharm.D. | President, Chief Executive Officer and Executive Director |
| Mark W. Hahn | Chief Financial Officer |
| Andrew Fisher | General Counsel |
| Dr. Kathleen A. Rickard M.D. | Chief Medical Officer |
| Victoria Stewart | Senior Director of Investor Relations and Communications |
| Matthew Casbon | Vice President of Sales, Marketing and Training |
| Ostra Jewell | Senior Vice President of Human Resources |
| Dr. Tara Rheault M.P.H., Ph.D. | Chief Development Officer |
| Christopher Martin | Chief Commercial Officer |
| Caroline Diaz | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 8-K | Current Report |
| Mar 18, 2025 | ARS | Filing |
| Mar 18, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2025 | 144 | Filing |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 21, 2025 | SCHEDULE 13D/A | Filing |